- Home
- MIN vs DRTS Comparison
MIN vs DRTS Comparison
Compare MIN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- DRTS
- Stock Information
- Founded
- MIN 1988
- DRTS 2015
- Country
- MIN United States
- DRTS Israel
- Employees
- MIN N/A
- DRTS N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- DRTS Medical/Dental Instruments
- Sector
- MIN Finance
- DRTS Health Care
- Exchange
- MIN Nasdaq
- DRTS Nasdaq
- Market Cap
- MIN 304.4M
- DRTS 262.6M
- IPO Year
- MIN N/A
- DRTS N/A
- Fundamental
- Price
- MIN $2.68
- DRTS $2.99
- Analyst Decision
- MIN
- DRTS Strong Buy
- Analyst Count
- MIN 0
- DRTS 2
- Target Price
- MIN N/A
- DRTS $8.00
- AVG Volume (30 Days)
- MIN 331.0K
- DRTS 51.5K
- Earning Date
- MIN 01-01-0001
- DRTS 05-19-2025
- Dividend Yield
- MIN 7.31%
- DRTS N/A
- EPS Growth
- MIN N/A
- DRTS N/A
- EPS
- MIN 0.08
- DRTS N/A
- Revenue
- MIN N/A
- DRTS N/A
- Revenue This Year
- MIN N/A
- DRTS N/A
- Revenue Next Year
- MIN N/A
- DRTS N/A
- P/E Ratio
- MIN $33.38
- DRTS N/A
- Revenue Growth
- MIN N/A
- DRTS N/A
- 52 Week Low
- MIN $2.52
- DRTS $1.75
- 52 Week High
- MIN $2.88
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- MIN 51.79
- DRTS 55.04
- Support Level
- MIN $2.64
- DRTS $2.95
- Resistance Level
- MIN $2.68
- DRTS $3.12
- Average True Range (ATR)
- MIN 0.03
- DRTS 0.21
- MACD
- MIN -0.00
- DRTS -0.00
- Stochastic Oscillator
- MIN 66.67
- DRTS 31.33
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.